The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood.
Winda AriyaniMiski Aghnia KhairinisaGaetano PerrottaMario MantoNoriyuki KoibuchiPublished in: Cerebellum (London, England) (2019)
Gadolinium (Gd)-based contrast agents (GBCAs) are used in magnetic resonance imaging (MRI) to increase the diagnostic yield. Current reports using animal models or human subjects have shown that GBCAs may be deposited in brain including the cerebellum. Although further studies may be required to clarify the toxicity of GBCAs, we should be more cautious to use these agents particularly in patients who more likely to have repeated enhanced MRI along their lifespan. In this editorial, current studies to clarify the toxicity of GBCAs in the cerebellum are introduced.
Keyphrases
- contrast enhanced
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- diffusion weighted imaging
- endothelial cells
- oxidative stress
- healthcare
- primary care
- case control
- white matter
- preterm birth
- cerebral ischemia
- depressive symptoms
- emergency department
- resting state
- multiple sclerosis
- functional connectivity
- oxide nanoparticles
- subarachnoid hemorrhage
- brain injury
- pregnancy outcomes
- adverse drug
- pluripotent stem cells